MACOM's £45m IQE Stake Tests UK Semiconductor Independence

The deal, announced on 28 May 2026 according to IQE's regulatory filings, is structured as £30m in equity and £15m in non-interest-bearing convertible loan notes. It arrives at a moment when IQE's balance sheet is at its thinnest in years, and when demand for the company's Indium Phosphide wafers, critical to AI and data centre infrastructure, is accelerating. The combination of financial weakness and strategic value created the conditions for a transaction that hands MACOM meaningful influence over a key European semiconductor supplier.

What MACOM is buying, and what it gets in return

MAcom (Nasdaq: MTSI), a US-headquartered compound semiconductor firm with a market capitalisation of approximately $8bn, is not making a passive financial bet. The investment comes bundled with long-term supply agreements, according to the company's announcement, suggesting vertical integration motives: securing access to IQE's epitaxial wafer production for MACOM's own product lines.

Two MACOM executives will join IQE's board as non-executive directors. Robert Dennehy, MACOM's chief operating officer, and David O'Carroll, a vice president at the firm, will take seats immediately. IQE disclosed that it has entered into a side letter granting MACOM "limited consent rights," though the precise scope of those rights has not been made public.

The appointment of two operational, rather than financial, executives to the board is notable. It signals that MACOM intends to be closely involved in production planning and capital allocation decisions, not merely to collect dividends or wait for a share price recovery.

The remaining £36m of the fundraise comprised a £23m redemption and reinvestment of convertible loan notes by existing noteholders, alongside a £13m placing and retail offer, according to the company's filing.

The numbers behind IQE's balance-sheet squeeze

IQE's financial position explains why the company accepted a deal that dilutes both equity and boardroom control.

For the year ended 31 December 2025, revenue fell almost 18% to £97.3m, according to the company's results. Adjusted EBITDA dropped 60% to just £3.2m. The adjusted loss before tax widened from £22.3m in the prior year to £27.9m.

Cash and cash equivalents stood at £15.7m at year-end. Adjusted net debt rose from £18.8m in FY 2024 to £31.5m in FY 2025, a deterioration of nearly 68% in twelve months. After the fundraise and the repayment of IQE's revolving credit facility with HSBC Bank, the company expects net cash inflows of £27.9m, according to its announcement.

That figure restores some breathing room but leaves IQE thinly capitalised relative to its global manufacturing asset base, which spans facilities in Cardiff, Newport, Massachusetts and Singapore. The company also disclosed that it intends to appoint a permanent chief financial officer "in due course," a vacancy that adds to the sense of a business in transition.

Photonics up, wireless down: a tale of two divisions

The most striking feature of IQE's results is the divergence between its two principal revenue streams.

Photonics revenue grew 15% year-on-year to £57.1m, driven by funding releases for US military and defence programmes in the second half of 2025, as well as continued growth in AI and data centre markets, according to the company. This is the division that produces the Indium Phosphide wafers used in high-speed optical interconnects, a component facing surging demand as hyperscale data centres expand.

Wireless revenue fell 40% to £40.1m, reflecting what IQE described as uncertain macroeconomic conditions in the first half of the year and softness in mobile handset demand.

The gap between the two divisions explains MACOM's interest. As a manufacturer of analogue and mixed-signal semiconductors for data centre, telecom and defence end markets, MACOM's product roadmap aligns closely with IQE's photonics business. The long-term supply agreements bundled into the investment reinforce that alignment.

"The £81m fundraise from key partners is a transformational investment for IQE, giving us the balance sheet strength to invest in our future growth, while maintaining our global asset base," said Jutta Meier, chief executive of IQE, in the company's announcement.

Meier also pointed to accelerating demand for Indium Phosphide solutions supporting data centre and AI markets as "a material growth driver throughout 2026 and beyond," according to the same statement.

What the deal structure signals for UK semiconductor firms

The MACOM-IQE transaction is worth examining not just for what it means for one Cardiff company, but for what it reveals about the position of UK semiconductor firms in an increasingly contested global supply chain.

First, the structure. MACOM has secured board seats, consent rights and supply agreements in exchange for capital. This is not a minority equity investment with limited strings attached. It is a package designed to give the investor operational influence proportionate to the financial risk it is assuming. For any UK scale-up negotiating with a larger strategic partner, the lesson is straightforward: the weaker the balance sheet, the more control the incoming investor will extract.

Second, the context. Compound semiconductors, particularly those based on Indium Phosphide and Gallium Arsenide, sit at the intersection of several sectors attracting intense government and corporate attention: artificial intelligence infrastructure, defence electronics and advanced telecommunications. IQE is one of a small number of global suppliers with the capacity to manufacture these materials at scale. That strategic position is what makes the company attractive to MACOM, but it also raises questions about whether UK and European policymakers are comfortable with a US firm gaining significant influence over a critical supplier.

The UK government's National Semiconductor Strategy, published in 2023, identified compound semiconductors as an area of domestic strength. Cardiff and the surrounding South Wales cluster, which includes the Compound Semiconductor Applications Catapult, has been positioned as a national asset. Whether the MACOM investment is viewed as a welcome injection of capital and demand, or as a gradual loss of strategic autonomy, will depend on the terms of those undisclosed consent rights.

Third, the competitive dynamics. IQE's wireless revenue decline of 40% underscores how exposed single-product semiconductor suppliers are to cyclical swings in consumer electronics. The photonics division's growth offers a hedge, but only if the company can invest in capacity quickly enough to capture the AI-driven demand wave. The MACOM capital is intended to fund that expansion, but it comes with strings that may constrain IQE's ability to serve competing customers on equal terms.

For UK firms in adjacent supply chains, the deal is a case study in the trade-offs that arise when strategic value outpaces financial resilience. IQE's technology is in demand. Its balance sheet was not strong enough to capitalise on that demand independently. MACOM stepped in with capital, but also with conditions that reshape the company's governance. The question now is whether IQE can use the investment to rebuild its financial position before those conditions become constraints.